Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma? by Vucur, Mihael et al.
www.impactjournals.com/oncotarget/ Oncotarget, September, Vol.1, No 5
Oncotarget 2010; 1:  373 - 378www.impactjournals.com/oncotarget 373
Mouse models of hepatocarcinogenesis: What can we learn for 
the prevention of human hepatocellular carcinoma?
Mihael Vucur1,*, Christoph Roderburg1,*, Kira Bettermann1, Frank Tacke1, Mathias 
Heikenwalder2, Christian Trautwein1 and Tom Luedde1
1 Department of Internal Medicine III, University Hospital of RWTH Aachen, D- 52074 Aachen, Germany
2 Institute of Virology, Technical University München, Helmholtz Center München, D-81675 Munich, Germany
* Equal contribution
Correspondence to: Tom Luedde, M.D./Ph.D., e-mail: tluedde@ukaachen.de
Κeywords: HCC, mouse models, TAΚ1, DEN, inflammation, signaling
Received: July 27, 2010, Accepted: August 8, 2010, Published: September 13, 2010
Copyright: © Vucur et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
AbstrAct:
	 There	is	growing	evidence	that	chronic	inflammatory	processes	are	involved	in	
triggering	the	sequence	from	chronic	liver	injury	to	liver	fibrosis,	ultimately	leading	to	
liver	cancer.	In	the	last	years	this	process	has	been	recapitulated	in	a	growing	number	
of different mouse models. However, it has remained unclear whether and how these 
mouse	models	reflect	the	clinical	reality	of	human	hepatocellular	carcinoma	(HCC).	
 Research with animal models but also human liver specimens has indicated 
that	 the	 NF-κB	 signaling	 pathway	 might	 withhold	 a	 crucial	 function	 in	 the	
mediation	 of	 chronic	 hepatic	 inflammation	 and	 the	 transition	 to	HCC	 in	 humans.	
However,	 previous	 studies	 led	 to	 divergent	 and	 partly	 conflicting	 results	 with	
regards	to	the	functional	role	of	NF-κB	in	hepatocarcinogenesis.	Here,	we	discuss	
a	 new	 genetic	 mouse	 model	 for	 HCC,	 the	 liver-specific	 TAK1	 knockout	 mouse,	
which	 lacks	 the	 NF-κB	 activating	 kinase	 TAK1	 specifically	 in	 parenchymal	 liver	
cells.	 Molecular	 findings	 in	 this	mouse	model	 and	 their	 possible	 significance	 for	
chemopreventive strategies against HCC are compared to other murine HCC models. 
Hepatocellular carcinoma (HCC) represents the 
most common primary carcinoma of the liver [1]. In most 
instances, HCC arises in a setting of chronic inflammation 
and subsequent liver fibrosis [2]. Besides chronic 
alcohol consumption or drug abuse, autoimmunity or 
the uptake of liver toxins (e.g. Aflatoxin B1), infections 
with Hepatitis B- (HBV) and Hepatitis C-viruses (HCV) 
represent the main risk-factors for hepatocarcinogenesis 
[3, 4]. The world-wide spread of HBV and HCV not only 
in developing but also in industrialized countries has led 
to approximately 500 million people persistently infected 
with HBV or HCV. This resulted in a strong rise in HCC-
incidence. Consequently, HCC is the 5th most common 
cause for cancer related death world-wide; in some African 
or Asian countries HCC is even the first common cause for 
cancer related morbidity [3, 4]. In addition to its enormous 
clinical relevance, its unique pathophysiological features 
have made liver cancer research a field for studying 
basic molecular and cellular events driving chronic 
inflammation induced carcinogenesis, a process whose 
molecular underpinnings have largely remained elusive. 
Based on the wide range of these features, including 
immunology, tumor biology, genetics, metabolomics, 
cell biology etc., basic scientists from various research 
fields have focused their interest on the examination of 
animal HCC models. This will hopefully accelerate the 
discovery of new molecular mechanisms involved in 
hepatocarcinogenesis, subsequently leading to novel - 
urgently needed - therapeutic strategies against HCC. 
Only recently, small inhibitor molecules have 
entered clinical practice to treat patients suffering from 
HCC. As such, Sorafenib (Nexavar®) is one of the 
new therapeutic agents that inhibit both pro-angiogenic 
(VEGFR-1, -2, -3; PDGFR-β) and tumorigenic (RET, 
Flt-3, c-Kit) receptor tyrosine kinases. Its efficacy in the 
context of HCC treatment was demonstrated in two large 
phase III clinical trials (SHARP and Asia-Pacific trial), 
which were conducted in both Western and Asian countries 
[5, 6]. Besides sorafenib, further therapeutic agents like 
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regorafenib (BAY 73-4506) are currently investigated for 
their potential as anti-liver cancer therapeutics. 
However, these new therapeutics “only” prolong 
survival and are palliative, while substances that could be 
used in an adjuvant setting are still lacking. In addition, 
it has to be clearly stated that HCC represent a diverse 
spectrum of cancers that will likely need - depending on 
the tumor type and tumor stage - different therapeutic 
strategies. In summary, systemic therapeutic options for 
HCC treatment are currently limited, underlining the need 
for new molecular targets. As outlined above, it has been 
well established that chronic inflammation and fibrosis 
precedes hepatocarcinogenesis. The eradication of the 
most common cause of chronic hepatic inflammation 
in humans (infection with HBV and HCV) is currently 
unattainable. Therefore, identification of central 
inflammatory signaling pathways that drive the transition 
from chronic liver injury to dysplasia and HCC might 
indeed open new possibilities for HCC-chemoprevention 
in a setting of chronic hepatitis. 
In order to gain a better functional insight into the 
molecular mechanisms of hepatocarcinogenesis, multiple 
studies were performed using human HCC tissue. In 
the last years, a collection of genetic and epigenetic 
alterations, chromosomal aberrations, gene mutations and 
altered molecular pathways was described [7]. As such, 
chromosomal alterations could be attributed to certain 
genes potentially involved in hepatocarcinogenesis, such 
as c-Myc (8q), Cyclin A2 (4q), Cyclin D1 (11q), Rb1 
(13q), AXIN1 (16p), p53 (17p), IGFR-II/M6PR (6q), 
p16 (9p), E-Cadherin (16q), SOCS (16p), and PTEN 
(10q) [7, 8]. Further, chromosomal alterations could be 
described in HCC, of which amplifications of 1q (58%-
78%), 6p, 8q, 17q, and 20q, and deletions in 4q, 8p, 13q, 
16q, and 17p represented the most frequent ones [9, 10]. 
However, in many cases it was difficult to assess whether 
these alterations represented a correlative epiphenomenon 
or if they were causally linked to HCC pathogenesis. In 
the light of the apsects mentioned above animal-models 
for HCC offer a unique possibility to study mechanistic 
and cellular aspects of tumor biology, including genetics 
of tumor initiation and promotion, tumor progression 
and spreading (metastasis) in vivo. Moreover, animal 
models also represent a valuable tool to pre-screen 
various therapeutic compounds for their efficacy to inhibit 
particular signaling pathways and prevent or decelerate 
HCC development. 
The fact that inflammatory stimuli promote HCC 
development has been recapitulated in various rodent 
models and indeed during the last decades different 
models of chronic or acute liver damage induced 
carcinogenesis (e.g. chemically or genetically) have 
been established. One of the best studied chemically 
induced HCC-models is the diethylnitrosamine (DEN) 
induced liver carcinogenesis, which has been established 
in rats and mice [11]. In mice, a single dose of DEN at 
the age of 2 weeks causes DNA-damage, subsequent 
acute hepatitis, finally leading to HCC at approximately 
8-10 months of age. The DEN rodent model withholds 
several advantages: (1) it can easily be administered to 
mice from different genetic backgrounds and of different 
genotype, (2) it has a high HCC incidence and (3) is highly 
reproducible [12]. Moreover, liver tumors from these 
mice withhold important features of a malignant cancer, 
since they metastasize in the lung. However, the primary 
event in DEN-induced carcinogenesis is DNA-damage 
leading to genetic mutations in an otherwise healthy 
liver. This indicates that - although happening in the 
context of acute liver damage - the sequence of primary 
DNA-damage and secondary acute inflammation does 
not quite reproduce the clinical reality of most patients, 
which develop HCC on the basis of chronic hepatitis in 
the absence of mutagens. Still, the DEN-rodent model has 
revealed crucial molecular and cellular pathways involved 
in the development of liver cancer and is a valuable tool 
to investigate particular molecules for their potential in 
inhibiting or promoting liver cancer formation [12-14].
In contrast to the DEN-rodent model, the Mdr2-
knockout mouse represents a prototype of a genetically 
modified mouse model used to identify the pathways 
responsible for chronic inflammation-induced liver 
cancer. Mdr2-knockout mice lack a biliary transporter 
protein denoted as multi-drug resistance gene 2 (mdr2) 
leading to cholestatic hepatitis and liver cancer [15]. 
Tumor development in the Mdr2-knockout mice 
progresses through distinct phases: inflammation, 
dysplasia, dysplastic nodules, carcinoma and metastasis, 
thus mimicking to some degree the formation of HCC 
in humans [16]. A similar sequence of inflammation, 
mild fibrosis, dysplasia and HCC formation is observed 
in transgenic mice that overexpress the inflammatory 
cytokines lymphotoxin a and b (LTab) in the liver 
(AlbLTab) [17]. It was demonstrated that lymphotoxin 
LTa, b and their receptor (LTbR) are upregulated in livers 
of humans with HBV- or HCV-induced hepatitis and HCC. 
Subsequently, liver-specific LTab expression in mice 
induced liver inflammation and HCC [17]. In this context 
it is important to note that blockage of LTbR signaling 
strongly reduced the incidence of chronic hepatitis as well 
as abolished liver cancer [17].
The differences between the above mentioned 
rodent HCC-models are reflected by distinct, activated 
inflammatory signaling pathways leading to inflammation 
and hepatocarcinogenesis. One of the most important 
and best-studied inflammatory signaling cascades 
involved is - indeed - the NF-kB pathway. NF-kB can 
be activated by different stimuli like tumor necrosis 
factor or Interleukin-1 and controls the transcription 
of inflammatory and anti-apoptotic genes [18]. One 
important step in the activation of NF-kB is represented 
by activation of a high-molecular-weight kinase complex, 
the so-called IKK complex, consisting of two catalytic 
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subunits, IKK1 (IKKa) and IKK2 (IKKb), as well as a 
regulatory subunit called NEMO (IKKg). Upon activation 
of this pathway by TNF, the IKK complex is recruited to 
adaptor proteins like TRAF2 and RIP1 and is activated by 
the kinase TAK1, so it can phosphorylate the inhibitory 
protein IkBa and mediate nuclear translocation of NF-
kB (Fig. 1). In the DEN-rodent model, inhibition of NF-
kB by conditional liver specific deletion of IKK2 led to 
increased liver-tumor formation [19], suggesting that the 
proinflammatory NF-kB signaling pathway suppresses 
hepatocarcinogenesis. In contrary, inhibition of the NF-
kB signaling in the Mdr2-knockout mouse led to a strong 
decrease in hepatocarcinogenesis compared to mice 
with proficient NF-kB signaling, arguing for a tumor-
promoter-function of this pathway [16]. Similarly, lack of 
NF-kB signaling strongly decreased chronic hepatitis and 
prevented hepatocarciniogenesis in the LT ab liver-tumor 
model, with the only difference that liver tumor formation 
also occurred in the absence of TNFR1 [17]. The reason 
for this obvious contradiction between the different 
murine HCC models has not been solved, meaning that 
it is presently not clear if NF-kB inhibition might be an 
option for chemoprevention of hepatocellular carcinoma 
in humans. Possibly, suppression of NF-kB signaling 
might be only beneficial for particular subtypes of human 
HCC – but this will need further investigation.
 How can this contradictory role of IKKb signaling 
in HCC formation be reconciled? On the one hand IKKb 
signaling might be required for hepatocytes to respond to 
and survive carcinogenic stimuli and acute liver injury 
(e.g. DEN exposure). On the other hand, IKKb signaling 
might enable local chemokine expression by hepatocytes 
subsequently leading to chronic inflammation and HCC 
(e.g. like in the AlbLTab mouse model). Consistent with 
this hypothesis is the finding that AlbLTab x Rag1-/- mice 
were devoid of chronic hepatitis, hepatocyte or oval-cell 
proliferation and failed to develop HCC. 
Why could immune cells be essential for liver 
tumorigenesis? One explanation would be that CD4+ or 
CD8+ T-cells expressing inflammatory cytokines (e.g. 
IL1b, TNF, IFNg) as well as cytolytic proteins (e.g. 
Granzyme B) might contribute to hepatocyte cell death 
and tissue remodeling and transformation, finally leading 
to HCC [20]. Consequently, the role of NF-kB signaling 
in hepatocarcinogenesis might depend on the mouse 
model and the type or degree of liver inflammation and 
injury [21].
To further dissect the role of NF-kB in 
hepatocarcinogenesis we recently studied the roles of the 
molecules NEMO and TAK1 in hepatocarcinogenesis 
[22]. As mentioned above, both of these molecules 
are involved in controlling the activation of NF-kB in 
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Figure 1: Activation of canonical NF-κB signaling by TNF-α. Association of TNF-R1 results in TRADD-dependent TRAF2 and 
RIP1 recruitment. TRAF2 mediates K63-linked ubiquitination of RIP1 and recruits the IKK complex via the catalytic subunit NEMO. 
Autoubiquitination of TRAF2 causes TAK1 activation by interaction via TAB2/3. In cosequence TAK1 phosphorylate and activate IKKβ, 
which in turn phosphorylate IκBα, leading to his proteasomal degradation and releases NF-κB.
Oncotarget 2010; 1:  373 - 378376www.impactjournals.com/oncotarget
various cellular systems [22-24] and are important in 
mediating inflammatory signaling pathways. Surprisingly, 
conditional deletion of NEMO as well as TAK1 in 
hepatocytes (referred to as NEMOLPC-KO and TAK1LPC-KO 
mice) leads to spontaneous HCC-development in mice 
(Fig. 2A). Hepatocarcinogenesis was preceded by hepatic 
inflammation and liver cirrhosis which progresses through 
distinct phases (hepatitis, liver fibrosis and dysplasia) to 
HCC (Fig. 2B). These findings support the hypothesis that 
at least some members of the NF-kB pathway function 
as a tumor suppressors, and our further results suggested 
that this mainly confers to IKK subunits and molecules 
upstream of the IKK-complex. However, it is presently 
unclear if these new genetic tumor models mirror any 
entity of human HCC. 
HCC of TAK1LPC-KO and NEMOLPC-KO mice 
were investigated in further detail on genomic 
and transcriptional level. Therefore, we compared 
chromosomal aberrations in micro-dissected tumors of 
TAK1LPC-KO and NEMOLPC-KO mice. Comparative genomic 
hybridization analysis (aCGH) revealed that all liver 
tumors seen in NEMOLPC-KO mice displayed chromosomal 
amplifications in a more or less random manner (data 
not shown). In contrast, TAK1LPC-KO mice displayed 
defined chromosomal amplifications within certain hot-
spot-areas on chromosomes 4, 8 and 13 [22]. These 
amplifications and deletions of chromosomal regions 
ranged from 0.68 megabase (MB) to 151 MB in TAK1LPC-
KO tumors and correlated with increased transcription of 
certain oncogenes located within the respective amplified 
chromosomal regions: Ntrk2, Net1 and Jun. These 
findings suggest completely different pathomechanisms 
of hepatocarcinogenesis between the TAK1- and NEMO-
models: Although both mice show a defective NF-kB-
activation in hepatocytes, only one model is associated 
with defined aberrations within certain chromosomal 
loci, upregulation of particular oncogenes as well as 
different histopathological features. This underlines that 
currently unknown molecular pathways downstream 
of TNF-associated molecules exist which might couple 
inflammation with specific genetic alterations as the basis 
for malignant transformation of hepatocytes. In this light, 
the new TAK1 model might represent an attractive model 
for a deeper understanding of these complex processes in 
Figure 2: (A) Representative macroscopic pictures of 7-9 weeks-old male WT (left panel), TAK1LPC-KO (middle panel) and 
NEMOLPC-KO livers (right panel). Histological features of liver tumors in TAK1LPC-KO and NEMOLPC-KO mice stained by H/E (lower panel, 
arrow head). TAK1LPC-KO liver showed a clear cell HCC whereas NEMOLPC-KO showed an eosinophilic, hepatoid HCC. (B) Serum level 
analysis of alanine aminotransferase (ALT), aspartate aminotransferase (AST). Results are shown as mean, error bars indicate SEM. **P<0.01, 
***P<0.001 (n=5 each genotype).
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the future, which might lead to a new chemopreventive 
strategy in patients with chronic hepatitis. 
Given the rising number of genetic or chemical 
murine HCC models, the question remains if all these 
models are of significance for the understanding of human 
hepatocarcinogenesis and which of these models reflect 
which type of HCC in patients. This question could be 
addressed by a more systematic approach to compare 
specific molecular and genetic features between the 
different murine HCC models. As such, chromosomal 
aberrations in the various murine models, histopathology, 
transcriptional and metabolic changes could be compared 
at different stages of tumor initiation and promotion and 
correlated with the development of HCC in cirrhotic 
transformed livers. The same applies to signalome and 
transcriptome analyses or the possible role of hepatic stem 
cells during tumorigenesis. 
The absence of a curative pharmacological treatment 
approach for human HCC and the limitations of the present 
molecular inhibitors in the palliative situation clearly 
underline the need for the identification of novel target 
molecules. The unique inflammation- carcinogenesis 
sequence in HCC suggest that such specific inhibitors 
against inflammatory signaling pathways may allow to 
intercept the continious transition from chronic liver 
injury to HCC. A systematic analysis of the various 
available murine liver cancer models might be the basis 
for the future identification of these potential targets and 
might open the door to the successful chemoprevention 
against liver cancer. 
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